pufa 18:2 i

PUFA 18:2 i refers to linoleic acid, an 18‑carbon polyunsaturated fatty acid with two cis double bonds belonging to the omega‑6 family. It is designated chemically as cis‑9,12‑octadecadienoic acid and is the most abundant polyunsaturated fatty acid in many human diets. Linoleic acid cannot be synthesized by human enzymes because mammals lack the Δ12 desaturase necessary to introduce double bonds at the n‑6 position; therefore, it is classified as an essential fatty acid that must be obtained through diet. Functionally, linoleic acid is incorporated into membrane phospholipids, contributing to membrane fluidity and cellular signalling. In the body, linoleic acid serves as a precursor to longer and more highly unsaturated omega‑6 fatty acids through desaturation and elongation pathways. These derivatives include gamma‑linolenic acid (GLA) and arachidonic acid (ARA), which give rise to eicosanoids—bioactive lipid mediators that regulate inflammation, immunity, and hemostasis. The balance between omega‑6 and omega‑3 PUFA influences the nature of these signalling compounds, with implications for inflammatory processes and cardiovascular health. Polyunsaturated fatty acids, including linoleic acid, are integral to lipid metabolism, energy storage, and the structural integrity of all cell types, from hepatic tissue to neurons.

Linoleic acid (PUFA 18:2 i) exerts multiple physiological effects beyond serving as a structural lipid. Key functions include maintaining cell membrane fluidity and participating in signal transduction pathways. As the primary omega‑6 fatty acid in Western diets, linoleic acid influences lipid metabolism and cardiovascular risk profiles. Consumption of linoleic acid in place of saturated fats has been associated with favorable changes in blood lipid levels, including reductions in total cholesterol and low‑density lipoprotein (LDL) cholesterol, which are established risk factors for atherosclerosis. Emerging evidence supports associations between higher dietary linoleic acid and reduced risk of type 2 diabetes. A systematic review and meta‑analysis of prospective cohort studies found that higher intakes of linoleic acid were significantly associated with lower risk of type 2 diabetes, with each 5% increase in energy from linoleic acid correlating with an approximately 10% lower risk. The mechanisms may include improved insulin sensitivity and modulation of cell membrane composition in skeletal muscle and adipose tissue. Linoleic acid is also a precursor for bioactive lipid mediators. Through enzymatic desaturation and elongation, it contributes to the biosynthesis of arachidonic acid, which is converted into eicosanoids such as prostaglandins and leukotrienes. These compounds play nuanced roles in inflammation and immunity. While some derivatives are pro‑inflammatory, they are essential for acute immune responses and tissue repair. Balanced intake of omega‑6 and omega‑3 fatty acids is thought to influence the profile of eicosanoids produced, with potential implications for chronic inflammation and related disorders. In cell culture and animal models, modulation of PUFA composition affects signalling pathways linked to metabolic regulation, oxidative stress, and gene expression.

Quantifying the optimal intake of linoleic acid involves understanding both deficiency prevention and potential health benefits. Dietary Reference Intakes established in North America provide Adequate Intake levels for linoleic acid to prevent essential fatty acid deficiency. For adult males, the Adequate Intake is approximately 17 g per day, and for adult females approximately 12 g per day, based on typical energy intake levels and requirements for essential fatty acid sufficiency. These intake values increase modestly during pregnancy and lactation due to the demands of fetal development and milk production. Children and adolescents have proportionately lower Adequate Intake values, reflecting differences in body size and metabolic needs. For example, young children may require around 7–10 g per day, with incremental increases throughout childhood and adolescence. These recommended intakes ensure that tissues have sufficient linoleic acid to support growth, neural development, and skin integrity. In clinical settings, inadequate linoleic acid intake can lead to biochemical markers of deficiency, prompting adjustments in dietary fat composition. Factors influencing requirements include overall dietary fat intake, the ratio of omega‑6 to omega‑3 fatty acids, and individual metabolic capacity. Since linoleic acid competes with alpha‑linolenic acid (an omega‑3 fatty acid) for desaturase enzymes, extremely high intakes of one class may impact synthesis of derivatives from the other. Therefore, achieving a balanced intake of both omega‑6 and omega‑3 PUFA is often advised for optimal health outcomes. Current dietary surveys indicate that average intakes in Western populations exceed minimum requirements, but attention to food quality and balance can further refine health benefits.

True deficiency of linoleic acid is rare in populations consuming varied diets due to the widespread presence of vegetable oils, nuts, seeds, and animal products. However, when deficiency does occur, it manifests as specific clinical signs reflecting the essential role of this fatty acid in skin, immune function, and growth. One of the earliest and most recognizable signs of essential fatty acid deficiency is scaly dermatitis, characterized by dry, flaky skin, erythema, and pruritus. Hair loss (alopecia) and brittle nails may accompany skin changes. In infants, inadequate linoleic acid can impair growth and neural development, with visible impacts on weight gain and developmental milestones. At a biochemical level, deficiency is reflected by elevations in triene/tetraene ratios in plasma phospholipids, a marker used in clinical diagnostics. Severe or prolonged deficiency impairs wound healing and compromises barrier function, increasing susceptibility to infections. Infants fed formulas lacking essential fatty acids historically exhibited deficiency symptoms, which resolved upon reintroduction of linoleic acid. In adults, deficiency has been documented in individuals receiving long‑term parenteral nutrition without adequate essential fatty acids, leading to dermatitis, alopecia, and increased infections. Populations at risk for deficiency include those with extremely low dietary fat intake due to malnutrition or restrictive diets, individuals with fat malabsorption disorders such as cystic fibrosis or chronic pancreatitis, and patients on intravenous feeding regimens lacking essential fatty acids. While biochemical deficiency is uncommon, suboptimal intakes combined with imbalanced omega‑6 to omega‑3 ratios may influence inflammatory and metabolic health.

Linoleic acid is abundant in many plant‑based foods, particularly seed oils, nuts, and seeds. Safflower oil is among the richest sources, providing very high amounts of linoleic acid per tablespoon. Grapeseed oil and sunflower oil are similarly dense sources of this essential fatty acid. Corn oil and soybean oil are commonly used in cooking and processed foods, contributing substantially to linoleic acid intake in many diets. Smaller but significant contributions come from nuts such as walnuts, black walnuts, pistachios, and almonds, and seeds including pumpkin, hemp, and sunflower seeds. Animal products also contain linoleic acid, though at lower concentrations than plant oils. Poultry, eggs, and certain meats reflect the fatty acid composition of the animal’s diet; pasture‑fed animals may have different profiles compared to grain‑fed counterparts. Dairy products contain linoleic acid in the fat fraction, albeit in modest amounts relative to oils and nuts. Edamame (soybeans) and other legumes contribute both protein and linoleic acid. Incorporating a variety of these foods supports meeting adequate intake levels. For example, a single tablespoon of safflower or sunflower oil can provide several grams of linoleic acid, while a one‑ounce serving of walnuts or pumpkin seeds adds additional valuable fatty acids. Combining oils, nuts, and seeds into meals and snacks enhances both essential fatty acid intake and overall diet quality. Attention to preparation methods is important as heating can oxidize polyunsaturated fats; using these oils in dressings or low‑heat cooking preserves nutritional value.

Linoleic acid is absorbed in the small intestine as part of dietary triglycerides and phospholipids. Bile salts emulsify fats to form micelles, facilitating uptake by enterocytes. Within enterocytes, linoleic acid is re‑esterified and incorporated into chylomicrons, which transport it through the lymphatic system into circulation. Efficient absorption requires adequate pancreatic enzyme activity and bile production; disorders that impair these processes can reduce linoleic acid uptake. Bioavailability is influenced by the food matrix and preparation. Fats consumed with a meal containing other macronutrients are generally well absorbed. High amounts of soluble fiber or phytates may modestly reduce fat absorption by binding bile acids, though the clinical significance is limited. Oxidation of polyunsaturated fatty acids during high‑heat cooking can reduce their nutritional quality, underscoring the benefit of using linoleic acid‑rich oils in dressings or low‑heat applications. Once absorbed, linoleic acid is incorporated into cell membranes or metabolized via desaturation and elongation pathways. The efficiency of conversion to longer‑chain derivatives like arachidonic acid varies among individuals and is influenced by genetic and nutritional factors.

Most individuals consuming a varied diet obtain sufficient linoleic acid without supplementation. Linoleic acid supplements are available as concentrated forms of vegetable oils, including safflower, sunflower, and corn oil capsules. These may be considered in specific scenarios where dietary intake is inadequate or essential fatty acid needs are elevated. However, supplementation should be approached cautiously, as excessive intake of omega‑6 fatty acids relative to omega‑3s may shift the balance of eicosanoid production toward pro‑inflammatory pathways. Clinical trials have explored linoleic acid supplementation for conditions such as eczema and metabolic syndrome, with mixed results. In populations with low baseline intakes, increasing linoleic acid can correct deficiency and improve skin and growth outcomes. For most adults in Western countries, average linoleic acid consumption already exceeds minimum requirements. Instead of isolated supplementation, focusing on balanced dietary patterns that include both omega‑6 and omega‑3 sources is often more beneficial. When supplements are used, choosing products with minimal oxidation and consuming them with meals enhances tolerance and absorption. Consultation with a healthcare provider is recommended, particularly for individuals with inflammatory conditions, cardiovascular risk factors, or those taking medications that affect lipid metabolism.

Formal tolerable upper intake levels for linoleic acid have not been established, reflecting limited evidence of acute toxicity at typical dietary intakes. However, extremely high intakes far above Adequate Intake levels may influence metabolic pathways. Excessive consumption of omega‑6 fatty acids without concomitant omega‑3 intake may promote a higher ratio of pro‑inflammatory eicosanoids, potentially contributing to chronic inflammatory states. Observational studies suggest that replacing saturated fats with polyunsaturated fats, including linoleic acid, up to around 10% of energy may be associated with cardiovascular benefits. Nonetheless, intakes that exceed this proportion by a large margin may warrant balance with omega‑3 sources to mitigate potential adverse effects. Individuals with conditions such as inflammatory disorders or coronary artery disease should discuss dietary fat composition with healthcare professionals to optimize ratios of polyunsaturated fats in their diets.

Linoleic acid does not have well‑documented direct drug interactions like some vitamins or minerals. However, because it influences lipid metabolism and inflammatory pathways, it may interact indirectly with medications that affect these systems. For example, antihyperlipidemic drugs such as statins and fibrates modify lipid profiles; concurrent high intake of polyunsaturated fatty acids can influence circulating lipid concentrations and should be monitored. Anticoagulant medications (e.g., warfarin) act on clotting pathways that eicosanoids also modulate; substantial changes in dietary fat composition could theoretically alter prostaglandin synthesis, although clinical evidence is limited. Patients on drugs affecting lipid or inflammatory pathways should discuss dietary fat intake with their healthcare team to ensure comprehensive management.

Common Forms: Safflower oil capsules, Sunflower oil capsules, Mixed omega‑6 supplements

Typical Doses: Supplement doses vary; dietary intake usually sufficient

When to Take: With meals to improve tolerance

Best Form: Triglyceride form in oil capsules

⚠️ Interactions: May influence lipid‑modifying drug effects